Clinical trial
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With…
NCT04241068 · Biogen, Industry · Terminated
Key facts
| NCT number | NCT04241068 |
|---|---|
| Title | A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 |
| Official title | Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 |
| Lead sponsor | Biogen, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Aducanumab |
| Enrollment | 1,696 |
| Start date | Mar 2, 2020 |
| Primary completion | Jul 22, 2024 |
| Completion | Jul 22, 2024 |
| First posted | Jan 27, 2020 |
| Last update posted | Feb 21, 2025 |
| Countries | Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Japan, Netherlands, Poland and 8 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: